TCM
CTKB icon

Tradewinds Capital Management’s Cytek Biosciences CTKB Stock Holding History

Tradewinds Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed – – 502
2022
Q1 		$0 Hold
2
– – ﹤0.01% 789
2021
Q4 		$0 Hold
2
– – ﹤0.01% 777
2021
Q3 		$0 Buy
+2
New +$47 ﹤0.01% 761

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Tradewinds Capital Management's CTKB Position: Q2 2022 in Review

Tradewinds Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2022, closing a stake of 2 shares.

Tradewinds Capital Management first reported a position in CTKB in Q3 2021 and held it in 3 quarters. The position peaked at $0 in Q1 2022. 84 funds tracked by Wall St. Rank hold CTKB as of Q2 2022.

  • Tradewinds Capital Management reported no remaining Cytek Biosciences position as of Q2 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 2 Cytek Biosciences shares in Q2 2022.
  • Tradewinds Capital Management first reported a position in Cytek Biosciences in Q3 2021 and held it in 3 quarters.
  • Tradewinds Capital Management's Cytek Biosciences position peaked at $0 in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2022.

Based on Tradewinds Capital Management's 13F filing for Q2 2022, filed 21 Jul 2022.